Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Joint Corp. (The) (JYNT)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$7.51+4.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.39 → 0.39 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for JYNT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Open 30 to 35 new franchised clinics in 2026 | aims to open 30 to 35 new franchised clinics in 2026. | Intact | new franchised clinic openings fall below 30 in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “New franchised clinic openings, excluding the impact of refranchised clinics, are now expected to be in the range of 22 to 26.” “• New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be in the range of 30 to 35.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a franchise-growth business in the middle of a shift toward a pure-play franchisor. The long-term thesis is intact, while the latest signal has turned mixed and the business remains loss-making with elevated risk.
Valuation is expensive versus peers, and the expectations gap is meaningful. The evidence flags the valuation as unjustified, though the overall fragility rating is low because the concern is valuation alone, not a combination of expensive valuation, weak fundamentals, and turbulence.
Near-term performance is mixed: second-quarter system-wide sales fell year over year, and management lowered its forecast for new franchised clinic openings while keeping its sales guidance range. Refranchising is near completion, but recent quarters include a reported earnings miss and the next results carry elevated risk.
Over the multi-year view, the thesis depends on completing the shift to a franchisor model and turning clinic growth and system-wide sales into sustained progress. Near term, a guidance cut or further labor-market weakening would weigh on the setup, while continued strength from healthcare sector bellwethers would support it.
The long-term thesis remains intact, but the mixed execution record and expensive valuation make franchise growth and upcoming guidance important tests over the next 1 to 3 years. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain stable and effective management execution | A supporting condition in Joint Corp. (The)'s published investment case. The stated target is management status remains stable or improves. | Under Pressure | management execution deteriorates causing missed targets or strategy shifts | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve system-wide revenue between $519M and $552M in 2026 | A primary condition in Joint Corp. (The)'s published investment case. The stated target is revenue between $519 million and $552 million. | Intact | annual revenue falls below $519 million in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “2026 Guidance The Company reiterated its 2026 financial guidance as originally provided on March 12, 2026, as follows: • System-wide sales are expected to be between $519 million and $552 million.” “2026 Guidance The Company reiterated 2026 guidance as originally provided on March 12, 2026, as follows: • System-wide sales are expected to be between $519 million and $552 million.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.43 → $0.39 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-07-25 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-07-26 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-07-27 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-07-28 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-07-29 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-07-30 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-07-31 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-08-01 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-08-02 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-08-03 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-08-04 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-08-05 | $0.43 | $62,122,670 | 3 / 3 |
| 2026-08-06 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-08-07 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-08-08 | $0.30 | $62,222,670 | 2 / 3 |
| 2026-08-09 | $0.30 | $62,222,670 | 2 / 3 |
| 2026-08-10 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-08-12 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-08-13 | $0.64 | $62,588,750 | 2 / 4 |
| 2026-08-14 | $0.30 | $62,122,667 | 2 / 2 |
| 2026-08-15 | $0.30 | $62,122,667 | 2 / 3 |
| 2026-08-16 | $0.30 | $62,122,667 | 2 / 3 |
| 2026-08-17 | $0.30 | $62,122,667 | 2 / 3 |
| 2026-08-18 | $0.30 | $62,122,667 | 2 / 3 |
| 2026-08-19 | $0.30 | $62,122,667 | 2 / 3 |
| 2026-08-20 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-21 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-22 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-23 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-24 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-25 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-26 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-27 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-28 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-29 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-30 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-08-31 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-01 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-02 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-03 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-04 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-05 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-06 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-07 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-08 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-09 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-10 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-11 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-12 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-13 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-14 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-15 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-16 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-17 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-18 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-19 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-20 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-21 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-22 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-23 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-24 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-25 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-26 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-27 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-28 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-29 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-09-30 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-01 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-02 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-03 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-04 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-05 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-06 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-07 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-08 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-09 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-10 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-11 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-12 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-13 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-14 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-15 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-16 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-17 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-18 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-19 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-20 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-21 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-22 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-23 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-24 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-25 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-26 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-27 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-28 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-29 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-30 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-10-31 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-11-01 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-11-02 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-11-03 | $0.39 | $62,588,750 | 2 / 3 |
| 2026-11-04 | $0.39 | $62,588,750 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.